1-3 of 3
Aida Botelho de Sousa
Close
Sort by
Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-140494
Published: 2020
Journal Articles

Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years

Ali Bazarbachi, MD PhD, Ariane Boumendil, Sr., PhD, Hervé Finel, Sr., MD PhD, Irma Khvedelidze, Joanna Romejko-Jarosinska, Alina Daniela Tanase, MDPhD, Saad Akhtar, MD, Tarek Ben Othman, Abdelghani Tbakhi, MD, Boris Afanasyev, MD PhD, Javier Briones, MD PhD, Zafer Gülbas, MD, Jean Elcheikh, MD, Rose-Marie Hamladji, MD PhD, Tugrul Elverdi, MD, Didier Blaise, MD, Carmen Martinez, MD PhD, Eleonora Alma, Kazimierz Halaburda, MD PhD, Aida Botelho de Sousa, Bertram Glass, Stephen Robinson, Silvia Montoto, MD, Anna Sureda Balari, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-138546
Published: 2020
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-3.
https://doi.org/10.1182/blood-2019-132405
Published: 2019